B+
Bull case
25%
Probability
Target price
$2.40
-8.4% vs current
OABI
OmniAbDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.40
-46.6% vs current
B-
Bear case
25%
Probability
Target price
$0.70
-73.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+4.3
Score
AI commentary
Monitoring view. Primary-source context is solid, and the peer set is now anchored more tightly to OmniAb’s own disclosed operating competitors rather than broad adjacent tools names, but forward visibility is still limited because OmniAb’s upside depends heavily on external partner milestones and on whether newer platform offerings translate into durable monetization. The deterministic prior remains neutral with low catalyst density, so this stays a cautious watchlist thesis rather than a high-conviction directional setup.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-06-30catalystH1 2026 partner readouts are the nearest sentiment testHigh impact
Management highlighted H1 2026 topline data expectations for Immunovant’s two Phase 3 batoclimab thyroid eye disease studies and Teva’s Phase 1b vitiligo trial for TEV-'408. Positive partner data would help validate OmniAb’s royalty-and-milestone optionality, but timing and outcomes remain outside OmniAb’s control [#8-K-2026-03-04].
2026-09-30eventH2 2026 partner milestones could refresh the revenue narrativeHigh impact
OmniAb’s March 4, 2026 press release pointed to H2 2026 topline data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and cutaneous lupus erythematosus, plus H2 2026 Phase 2a celiac disease data for TEV-'408. These are meaningful external checkpoints for milestone visibility, but they are still partner-controlled and several steps removed from OmniAb’s own income statement [#8-K-2026-03-04].
2026-12-31event2026 cash trajectory is a real overhang despite revenue guidanceHigh impact
OmniAb reported $54.0 million of cash, cash equivalents and short-term investments at December 31, 2025, while guiding 2026 revenue to $25 million-$30 million, GAAP costs and operating expenses to $80 million-$85 million, cash costs and operating expenses to $50 million-$55 million, and year-end cash to $30 million-$35 million. If partner inflows slip or spending runs high, financing risk could move back into focus [#8-K-2026-03-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology